Colorectal cancer
Changing the story
We are advancing breakthroughs to help patients take control of their futures. With ongoing innovation in precision medicine, we aim for brighter outcomes for patients facing colorectal cancer.
The fight against colorectal cancer carries on
Colorectal cancer is increasingly found in adults under 50. Which is why early detection has never been more important. Breakthroughs in precision medicine and innovative treatments are transforming care.
- 45
is the new recommended age to start colorectal cancer screening for average-risk adults - 51%
increase in colorectal cancer among adults under 50 since 1994 - Approximately
20%
of patients with colorectal cancer are diagnosed after it has already spread to other parts of the body - 91%
5-year survival rate for colorectal cancer when caught before it spreads to other parts of the body
A focus on colorectal cancer
Advancements in precision medicine are transforming colorectal cancer treatment. Treatments can be tailored to the unique genetic makeup of a patient’s tumor.
Biomarker testing for colorectal cancer can identify genetic mutations or changes in DNA. These changes can help determine prognosis, treatment options, and the likelihood of the cancer returning. Some examples of biomarkers found in colorectal cancer are MSI (microsatellite instability) high, KRAS, and BRAF.
Genetic changes drive abnormal tumor growth and cancer progression, which is when cancer worsens and spreads in the body. Patients whose tumors have these mutations often face a poorer prognosis and worse outcomes. Understanding how mutations work has led to the development of therapies specifically designed to target them in colorectal cancer.
Advancements in precision medicine are transforming colorectal cancer treatment. Treatments can be tailored to the unique genetic makeup of a patient’s tumor.
Pfizer offers targeted therapies for colorectal cancer and is working on advancements for specific tumor mutations.
Know your status: Why screening is important on the Tamron Hall Show
The recommended screening age for colorectal cancer has gone from 50 to 45. Why is this important? Tamron Hall talks with Candace Henley, a patient advocate and colorectal cancer survivor, and Dr. Cathy Eng, a leading cancer expert, about the latest in colorectal cancer screening and biomarkers.
Detect early, treat early
Colorectal cancer in younger adults
More adults under 50 are being diagnosed with colorectal cancer than ever before. Learn some of the potential reasons behind this trend and some steps to help reduce risk.
Colorectal cancer screening saves lives
Routine colorectal cancer screening can detect cancer earlier, even before symptoms appear. Discover the latest recommendations on screening tests.
Why biomarkers matter in colorectal cancer
Biomarkers can play a key role in colorectal cancer care. They can help doctors better diagnose, understand, and treat cancer with targeted approaches.
A focus on improving health equity
We’re working to overcome health inequities
Black people are 20% more likely to develop colorectal cancer than White people
Colorectal cancer is the second leading cause of cancer death for Native people
Some minority groups, including Ashkenazi Jews, are at a higher risk for colorectal cancer due to certain gene mutations
Sharing strength & support
Derrick’s life took an unexpected turn after a cancer diagnosis. Facing devastating news and a terminal prognosis, Derrick shares how a clinical trial gave him new hope and a future he didn’t think was possible.
Resources & community
Colorectal Cancer Alliance
Providing support, education, and advocacy to patients and caregivers affected by colorectal cancer.
Global Colon Cancer Association
Advocating for equitable access to quality colorectal cancer screenings, testing, treatments, and care.
Fight Colorectal Cancer
Leading the fight against colorectal cancer through awareness, research, and empowering patient voices.
Colontown
Patient-led community offering connection, education, and shared experiences for those navigating colorectal cancer.